Laboratory Studies
- Ammonia: Ammonia level as high as 1.5 times normal (up to 1200 mcg/dL) 24-48 hours after the onset of mental status changes is the most frequent laboratory abnormality. Ammonia level may return to normal in stages 4 and 5.
- Transaminases levels: ALT and AST levels increase to 3 times normal but may return to normal by stages 4 or 5.
- Bilirubin: Bilirubin levels are >2 mg/dL (usually < 3 mg/dL) in 10-15% of patients. If direct bilirubin level is >15% of total or total is >3 mg/dL, consider other diagnoses.
- Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are prolonged >1.5-fold in more than 50% of patients.
- Lipase and amylase: These levels are elevated.
- Serum bicarbonate: This level is decreased secondary to vomiting.
- BUN and creatinine: These levels are elevated.
- Glucose: Expect hypoglycemia, particularly in children younger than 1 year.
- Lactic dehydrogenase (LDH): This level may be high or low.
- Anion gap and venous blood gas: Determine anion gap and venous blood gas level to evaluate for metabolic acidosis.
- Urine specific gravity and ketones: Specific gravity is increased; 80% of patients have ketonuria.
Imaging Studies
- Head CT scanning may reveal cerebral edema, but the results are usually normal.
Other Tests
- Free fatty acids and amino acids (eg, glutamine, alanine, lysine): These levels may be elevated.
- Factors II, VII, IX, X, fibrinogen: These levels may be low due to the disruption of synthetic activities in the liver. Consumption may also contribute to low levels of coagulation factors. Platelets are usually normal.
- Electroencephalogram (EEG) may reveal slow-wave activity in the early stages and flattened waves in advanced stages.
- CSF opening pressure, CSF WBCs: Lumbar puncture (LP) should only be performed in hemodynamically stable patients. Opening pressure may or may not be increased; WBCs (usually lymphocytes) are 8/mm3 or fewer (8 X 109/L or fewer).
- Workup to exclude IEM must be performed and should include evaluation for defects of fatty-acid oxidation, amino and organic acidurias, urea-cycle defects, and disorders of carbohydrate metabolism. For additional information, see the eMedicine article Pediatrics, Inborn Errors of Metabolism.
Procedures
- Vascular access - Arterial and/or central venous
- Lumbar puncture if patient is hemodynamically stable and no signs of increased ICP
- Intubation to maintain airway and ventilation and to manage intracranial pressure
- Nasogastric tube placement to decompress the abdomen
- Bladder catheterization to monitor urine output
- Percutaneous liver biopsy may be indicated to exclude IEM or toxic liver disease.
- Placement of an intracranial device for intracranial pressure monitoring is indicated for patients with increased intracranial pressure.
- Coagulopathy must be corrected before invasive procedures.
CDC. Reye Syndrome 1990 Clinical Case Definition. Available at http://www.cdc.gov/ncphi/disss/nndss/casedef/reye_syndrome_current.htm.
CDC. National Reye syndrome surveillance--United States, 1982 and 1983. MMWR Morb Mortal Wkly Rep. Feb 3 1984;33(4):41-2. [Medline].
Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med. May 6 1999;340(18):1377-82. [Medline].
New World Encyclopedia. Reye's Syndrome. Last updated September 5, 2008. Available at http://www.newworldencyclopedia.org/entry/Reye%27s_syndrome.
Lovejoy FH Jr, Smith AL, Bresnan MJ, Wood JN, Victor DI, Adams PC. Clinical staging in Reye syndrome. Am J Dis Child. Jul 1974;128(1):36-41. [Medline].
Glasgow JF, Middleton B, Moore R, Gray A, Hill J. The mechanism of inhibition of beta-oxidation by aspirin metabolites in skin fibroblasts from Reye's syndrome patients and controls. Biochim Biophys Acta. May 31 1999;1454(1):115-25. [Medline].
Brunner RL, O'Grady DJ, Partin JC, Partin JS, Schubert WK. Neuropsychologic consequences of Reye syndrome. J Pediatr. Nov 1979;95(5 Pt 1):706-11. [Medline].
Casteels-Van Daele M, Van Geet C, Wouters C, Eggermont E. Reye syndrome revisited: a descriptive term covering a group of heterogeneous disorders. Eur J Pediatr. Sep 2000;159(9):641-8. [Medline].
CDC. Centers for Disease Control and Prevention. Follow-up on Reye syndrome-United States. MMWR CDC Surveill Summ. 1980;29:321.
CDC. Centers for Disease Control and Prevention. Reye syndrome-United States. MMWR CDC Surveill Summ. 1979;28:97.
Chang PF, Huang SF, Hwu WL, Hou JW, Ni YH, Chang MH. Metabolic disorders mimicking Reye's syndrome. J Formos Med Assoc. Apr 2000;99(4):295-9. [Medline].
Chow EL, Cherry JD, Harrison R, McDiarmid SV, Bhuta S. Reassessing Reye syndrome. Arch Pediatr Adolesc Med. Dec 2003;157(12):1241-2. [Medline].
Clark I, Whitten R, Molyneux M, Taylor T. Salicylates, nitric oxide, malaria, and Reye's syndrome. Lancet. Feb 24 2001;357(9256):625-7. [Medline].
De Vivo DC. Reye syndrome. Neurol Clin. Feb 1985;3(1):95-115. [Medline].
From the Centers for Disease Control. Reye syndrome surveillance--United States, 1989. JAMA. Feb 27 1991;265(8):960. [Medline].
Gauthier M, Guay J, Lacroix J, Lortie A. Reye's syndrome. A reappraisal of diagnosis in 49 presumptive cases. Am J Dis Child. Oct 1989;143(10):1181-5. [Medline].
Glasgow JF. Reye's syndrome: the case for a causal link with aspirin. Drug Saf. 2006;29(12):1111-21. [Medline].
Glasgow JF, Middleton B. Reye syndrome--insights on causation and prognosis. Arch Dis Child. Nov 2001;85(5):351-3. [Medline]. [Full Text].
Greene CL, Blitzer MG, Shapira E. Inborn errors of metabolism and Reye syndrome: differential diagnosis. J Pediatr. Jul 1988;113(1 Pt 1):156-9. [Medline].
Hall SM, Plaster PA, Glasgow JF, Hancock P. Preadmission antipyretics in Reye's syndrome. Arch Dis Child. Jul 1988;63(7):857-66. [Medline].
Hurwitz ES, Nelson DB, Davis C, Morens D, Schonberger LB. National surveillance for Reye syndrome: a five-year review. Pediatrics. Dec 1982;70(6):895-900. [Medline].
McGovern MC, Glasgow JF, Stewart MC. Lesson of the week: Reye's syndrome and aspirin: lest we forget. BMJ. Jun 30 2001;322(7302):1591-2. [Medline]. [Full Text].
Orlowski JP. Whatever happened to Reye's syndrome? Did it ever really exist?. Crit Care Med. Aug 1999;27(8):1582-7. [Medline].
Orlowski JP, Hanhan UA, Fiallos MR. Is aspirin a cause of Reye's syndrome? A case against. Drug Saf. 2002;25(4):225-31. [Medline].
Reye RD, Morgan G, Baral J. Encephalopathy and fatty degeneration of the viscera: a disease entity in childhood. Lancet. Oct 12 1963;2(7311):749-52. [Medline].
Rowe PC, Valle D, Brusilow SW. Inborn errors of metabolism in children referred with Reye's syndrome. A changing pattern. JAMA. Dec 2 1988;260(21):3167-70. [Medline].
Schror K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9(3):195-204. [Medline].
Tomasi LG. Treatment of Reye syndrome--importance of clinical staging. Ann Neurol. Aug 1980;8(2):201-2. [Medline].
Trauner DA. Treatment of Reye syndrome. Ann Neurol. Jan 1980;7(1):2-4. [Medline].
van Bever HP, Quek SC, Lim T. Aspirin, Reye syndrome, Kawasaki disease, and allergies; a reconsideration of the links. Arch Dis Child. Dec 2004;89(12):1178. [Medline].

